Pharming presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Today Pharming announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.
Today Pharming announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for RUCONEST® [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with hereditary angioedema (HAE).
Today Pharming announced that it has issued a total of 6,240,000 new shares following exercise of warrants representing a total of 6,240,000 shares.
Pharming presents its (unaudited) financial report for the six months ended 30 June 2018.
Pharming announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.
Pharming announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming presents its (unaudited) financial report for the quarter ended 31 March 2018.
On May 16th Hereditary Angioedema (HAE) patient organizations from around the world, led by HAEi (The international HAE patient organisation), come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.
The Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.
